Mersana Therapeutics, Inc.
(MRSN)
Add Watchlist
3.46 USD +0.16
Closed: 03 May, 3:55 pm
Symbol MRSN
Market Cap 417.2M
Price 3.46
Open 3.52
52-wk High 9.62
50 Day Avg 4.33
Earnings Announcement 2024-02-26
Website https://www.mersana.com
Name Mersana Therapeutics, Inc.
Shares Outstanding 120,582,000
Change % 2.9762%
Low 3.42
52-wk Low 0.80
200 Day Avg 2.55
Last Dividend 0.00
Exchange NASDAQ
Volume 1,170,039
Previous Close 3.36
High 3.63
EPS -1.76
PE -1.97
Avg Volume 2,246,400
CUSIP 59045L106
Mersana Therapeutics, Inc. Outlook
Description Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Currency USD
ISIN US59045L1061
Industry Biotechnology
Changes 0.10
CUSIP 59045L106
Range 0.80 - 9.62
Beta 1.37
CIK 0001442836

Mersana Therapeutics, Inc. News

28-Feb-2024 2:10 PM

Mersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call Transcript

Mersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call Transcript

28-Feb-2024 9:11 AM

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.44 per share a year ago.

27-Feb-2024 8:01 AM

Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences:

21-Feb-2024 8:00 AM

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, February 28, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

20-Feb-2024 11:06 AM

Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

22-Jan-2024 5:41 PM

3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024

Biotech stocks are some of the most exciting opportunities on the market.  Find the right ones with substantial catalysts and make a fortune.

31-Oct-2023 4:30 PM

Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2023 on Tuesday, November 7, 2023. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

18-Aug-2023 11:05 AM

After Plunging -68.18% in 4 Weeks, Here's Why the Trend Might Reverse for Mersana Therapeutics, Inc. (MRSN)

The heavy selling pressure might have exhausted for Mersana Therapeutics, Inc. (MRSN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

16-Aug-2023 10:59 AM

Down -64.71% in 4 Weeks, Here's Why Mersana Therapeutics, Inc. (MRSN) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Mersana Therapeutics, Inc. (MRSN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

08-Aug-2023 11:25 AM

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.55 per share a year ago.

27-Jul-2023 8:34 PM

EcoR1 Capital, LLC Acquires Significant Stake in Mersana Therapeutics Inc

San Francisco-based investment firm, EcoR1 Capital, LLC (Trades, Portfolio), recently executed a significant transaction involving the acquisition of shares in Mersana Therapeutics Inc. This article provides an in-depth analysis of the transaction, the profiles of both the guru and the traded company, and the potential implications of this deal.